FURUKAWA Yoichi

J-GLOBAL         Last updated: Nov 30, 2019 at 19:47
 
Avatar
Name
FURUKAWA Yoichi
Affiliation
The University of Tokyo
Section
The Institute of Medical Science The Advanced Clinical Research Center, Division of Clinical Genome Research
Job title
Professor
Degree
Ph.D.(The University of Tokyo)

Research Areas

 
 

Academic & Professional Experience

 
Apr 2007
 - 
Today
Professor, Division of Clinical Genome Research, IMS, UTokyo
 
Mar 2004
 - 
Mar 2007
Project professor, The 21st Center of Excellence Program, IMS, UTokyo
 
May 2001
 - 
Feb 2004
Associate professor, Human Genome Center, IMS, UTokyo
 
Feb 1999
 - 
Apr 2001
Assistrant professor, Human Genome Center, Institute of Medical Science (IMS), The University of Tokyo
 
Jun 1998
 - 
Jan 1999
Assistant professor, Department of surgery, The research hospital, IMSUT
 

Education

 
 
 - 
1987
Faculty of Medicine, The University of Tokyo
 

Published Papers

 
Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient
Yamaguch K, Shimizu E, Yamaguchi R, Imoto S, Komura M, Hatakeyama S, Noguchi R, Takane K, Ikenoue T, Gohda Y, Yano H, Miyano S, Furukawa Y
Journal of Human Genetics   64(8) 729-740   2019   [Refereed]
Anti-apoptotic effect by the suppression of IRF1 as a downstream of Wnt/β-catenin signaling in colorectal cancer cells
Ohsugi T, Kiyoshi Yamaguchi K, Zhu C, Ikenoue T, Takane K, Shinozaki M, Tsurita G, Yano H, Furukawa Y
Oncogene   38(32) 6051-6064   2019   [Refereed]
Deep sequencing across germline GWAS signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer
Ingle JN, Kalari KR, Momozawa Y, Kubo M, Furukawa Y, Shepherd LE, Ellis MJ, Goss PE, Barman P, Carlson EE, Sinnwell JP, Tang X, Goetz MP, Chen BE, Cairns J, Weinshilboum RM, Wang L
Pharmacogenetics and Genomics   29(8) 183-191   2019   [Refereed]
The Japanese society for cancer of the colon and rectum (JSCCR). Importance of gastric cancer for the diagnosis and surveillance of Japanese Lynch syndrome patients
Ikenoue T, Arai M, Ishioka C, Iwama T, Kaneko S, Matsubara N, Moriya Y, Nomizu T, Sugano K, Tamura K, Tomita N, Yoshida T, Sugihara K, Naruse H, Yamaguchi K, Nojima M, Nakamura Y, Furukawa Y
Journal of Human Genetics   64 1187-1194   2019   [Refereed]
Establishment and analysis of a novel mouse line carrying a conditional knockin allele of a cancer-specific FBXW7 mutation
Ikenoue T, Terakado Y, Zhu C, Liu X, Ohsugi T, Matsubara D, Fujii T, Kakuta S, Kubo S, Shibata T, Yamaguchi K, Iwakura Y, Furukawa Y
Sci Rep   8(1) 2021   2018   [Refereed]
Implementation of genomic medicine for gastrointestinal tumors
Furukawa Y
Ann Gastroenterol Surg   2(4) 246-252   2018   [Refereed][Invited]
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM
Pharmacogenet Genomics   28(6) 147-152   2018   [Refereed]
Genetic variation determines VEGF-A plasma levels in cancer patients
Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K
Sci Rep   8(1) 16332   2018   [Refereed]
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer
Johmura Y, Maeda I, Suzuki N, Wu W, Goda A, Morita M, Yamaguchi K, Yamamoto M, Nagasawa S, Kojima Y, Tsugawa K, Inoue N, Miyoshi Y, Osako T, Akiyama F, Maruyama R, Inoue JI, Furukawa Y, Ohta T, Nakanishi M
J. Clin Invest   128(12) 5603-5619   2018   [Refereed]
Efficacy of liquid-based genetic diagnosis of endometrial cancer
Matsuura M, Yamaguchi K, Tamate M, Satohisa S, Teramoto M, Iwasaki M, Sugita S, Hasegawa T, Koubo R, Takane K, Ikenoue T, Furukawa Y, Saito T
Cancer Sci   109(12) 4025-4032   2018   [Refereed]
Overview of BioBank Japan Follow-up Data in 32 Diseases
Hirata M, Nagai A, Kamatani Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Kiyohara Y, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y; BioBank Japan Cooperative Hospital Group., Matsuda K
J Epidemiol   27(3S) S22-S28   2017   [Refereed]
Cross-sectional analysis of BioBank Japan Clinical Data: A Large Cohort of 200,000 Patients with 47 Common Diseases
Hirata M, Kamatani Y, Nagai A, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Kubo M, Muto K, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y. BioBank Japan Cooperative Hospital Group., Matsuda K
J Epidemiol   27(3S) S9-S21   2017   [Refereed]
Overview of the BioBank Japan Project: Study Design and Profile
Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Mushiroda T, Murakami Y, Yuji K, Furukawa Y, Zembutsu H, Tanaka T, Ohnishi Y, Nakamura Y; BioBank Japan Cooperative Hospital Group., Kubo M
J Epidemiol   27(3S) S2-S8   2017   [Refereed]
Identification of FERM domain-containing protein 5 (FRMD5) as a novel target of β-catenin/TCF7L2 complex
Zhu C, Yamaguchi K, Osugi T, Terakado Y, Noguchi R, Ikenoue T, Furukawa Y
Cancer Sci   108(4) 612-619   2017   [Refereed]
Genetic alterations in Japanese extrahepatic biliary tract cancer
Noguchi R, Yamaguchi K, Ikenoue T, Terakado Y, Ohta Y, Yamashita N, Kainuma O, Yokoi S, Maru Y, Nagase H, Furukawa Y
Oncol Lett   14 877-884   2017   [Refereed]
Requirement of glycosylation machinery in Toll-like receptor responses revealed by CRISPR/Cas9 screening
Sato R, Shibata T, Tanaka Yu, Kato C, Yamaguchi K, Furukawa Y, Shimizu E, Yamaguchi R, Imoto S, Miyano S, Miyake K
Int Immunol   29(8) 347-355   2017   [Refereed]
Bidirectional reporter assay using HAL promoter and TOPFLASH improves specificity in high-throughput screening of Wnt inhibitors
Yamaguchi K, Zhu C, Ohsugi T, Yamaguchi Y, Ikenoue T, Furukawa Y
Biotechnol Bioeng   114(14) 2868-2882   2017   [Refereed]
Decreased expression of Interferon-induced protein 2 (IFIT2) by Wnt/β-catenin signaling confers anti-apoptotic properties to colorectal cancer cells
Ohsugi T, Yamaguchi K, Zhu C, Ikenoue T, Furukawa Y
Oncotarget   8(59) 100176-100186   2017   [Refereed]
Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells
Amagai Y, Fujiyuki T, Yoneda M, Shoji K, Furukawa Y, Sato H, Kai C
Sci Rep   6 24572   2016   [Refereed]
Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B is responsible for familial adenomatous polyposis
Yamaguchi K, Nagayama S, Shimizu E, Komura M, Yamaguchi R, Shibuya T, Arai M, Hatakeyama S, Ikenoue T, Ueno M, Miyano S, Imoto S, Furukawa Y
Sci Rep   6 26011   2016   [Refereed]

Research Grants & Projects

 
Investigation of mechanisms underlying human gastrointestinal cancer
Grant-in-Aid for Scientific Research
Application of genome information for clinics
Grant-in-Aid for Scientific Research
Genetic testing project for Hereditary non-polyposis colorectal cancer(HNPCC)
The Other Research Programs